ABVD

Doxorubicin, bleomycin, vinblastine and dacarbazine for classical Hodgkin lymphoma, with PET-adapted de-escalation

For clinicians and students · Regimen tutorial · Lymphoma · 8 min read · last reviewed September 30, 2026

Indications

ABVD is first-line therapy for classical Hodgkin lymphoma of all stages (BC Cancer LYABVD).

• Limited stage: usually 2 to 4 cycles, with or without involved-site radiotherapy. The plan depends on interim PET and risk group (eviQ ID 57).
• Advanced stage: up to 6 cycles, with bleomycin omitted after a negative interim PET (eviQ ID 56).
• Advanced-stage alternatives: bleomycin-free brentuximab vedotin-AVD (BV-AVD) and nivolumab-AVD (N-AVD) are now funded options in many jurisdictions.
• Different pathway: nodular lymphocyte-predominant Hodgkin lymphoma is treated separately.

Regimen table

BC Cancer LYABVD / eviQ ID 56 (the doses agree):

Cycle length: 28 days. Each cycle is two treatments, 14 days apart.

Number of cycles and PET adaptation (BC Cancer LYABVD): give ABVD × 2, then PET-CT, ideally between Day 21 and Day 28 of Cycle 2. Note that the definition of "PET-negative" differs by stage.

• Limited stage:
• PET-negative (Deauville 1–2): AVD × 2 more cycles with no bleomycin, then stop.
• PET-positive (Deauville 3–5) without progression: stop chemotherapy and go to involved-site radiotherapy.
• Advanced stage:
• PET-negative (Deauville 1–3): AVD × 4 more cycles (Cycles 3–6).
• PET-positive (Deauville 4–5) without progression: ABVD × 4 more cycles, with CT after Cycle 4 and CT plus PET at the end of treatment. If PET is still positive after 6 cycles, consider consolidative radiotherapy or a biopsy.

Many centres escalate PET-positive advanced-stage patients to BEACOPP-type therapy, as in RATHL. BC Cancer instead continues ABVD. Follow your institutional pathway.

Premedication & supportive care

• Antiemetics: highly emetogenic in both protocols, driven by dacarbazine.
• BC Cancer: SCNAUSEA HEC protocol.
• eviQ: NK1 antagonist (netupitant/palonosetron) plus dexamethasone.
• Give antiemetics on both Day 1 and Day 15.
• Bleomycin premedication: BC Cancer gives hydrocortisone 100 mg IV over 15–30 min before bleomycin on Days 1 and 15. This prevents the febrile reaction to bleomycin.
• Hepatitis B:
• BC Cancer classifies ABVD as high risk for HBV reactivation.
• Check HBsAg, anti-HBc and anti-HBs at baseline. Results must be reviewed before Cycle 2.
• If HBsAg or anti-HBc is positive, give antiviral prophylaxis per SCHBV (entecavir preferred).
• Growth factors: not used as primary prophylaxis with standard ABVD.
• BC Cancer adds G-CSF only after experience with earlier cycles, still at 100% doses, when the Day 1 or Day 15 ANC is below 0.6 × 10⁹/L. Options are filgrastim 5 mcg/kg daily × 5 from Day 7 and Day 21, or pegfilgrastim 6 mg on Day 2 and Day 16.
• eviQ notes that G-CSF with bleomycin may increase the risk of pulmonary toxicity. Use it only when needed to avoid delays.
• BV-AVD is different: primary G-CSF prophylaxis is mandatory (BC Cancer LYAVDBV) because febrile neutropenia rates are high.
• Fertility and contraception:
• ABVD is generally less gonadotoxic than alkylator-heavy regimens.
• Still offer fertility counselling and preservation before starting.
• Doxorubicin and dacarbazine are teratogenic.
• Vaccines: avoid live vaccines. Give seasonal influenza vaccine per local guidance.

Key toxicities

• Bleomycin pulmonary toxicity: interstitial pneumonitis progressing to fibrosis, which can be fatal.
• Risk rises with age over 60 (eviQ advises careful monitoring and early cessation), cumulative dose, renal impairment (bleomycin is renally cleared), smoking, prior or concurrent chest radiotherapy, high inspired oxygen, and possibly G-CSF.
• Warning signs are dry cough, dyspnoea, basal crackles, a falling DLCO and new infiltrates.
• Cumulative dose limits differ. BC Cancer says limiting the total to 270 units should reduce risk. eviQ says the lifetime cumulative dose should not exceed 400,000 IU, with risk rising beyond 300,000 IU.
• The PET-adapted approach usually keeps exposure to 4 doses (40 units/m²).
• Bleomycin acute effects: fever and chills, rarely an idiosyncratic hypotensive reaction, and skin effects such as hyperpigmentation and flagellate erythema.
• Anthracycline cardiotoxicity: six cycles deliver 300 mg/m² of doxorubicin. Late cardiac risk is also relevant after mediastinal radiotherapy.
• Vinblastine: neuropathy (less than vincristine), constipation and jaw pain. Vinblastine is fatal if given intrathecally.
• Dacarbazine: marked nausea and vomiting, flu-like symptoms, pain along the vein during infusion (slow the rate or dilute), and photosensitivity.
• Myelosuppression: neutropenia is common, but febrile neutropenia is relatively uncommon.
• Extravasation: doxorubicin and vinblastine are vesicants.
• Late effects for survivors: cardiac disease, second cancers (especially after radiotherapy) and hypothyroidism after neck radiotherapy. Survivorship planning matters because many patients are young.

Monitoring

• Baseline:
• CBC and differential, bilirubin, ALT, creatinine and HBV serology (BC Cancer).
• Pulmonary function tests including DLCO, and an assessment of cardiac function (echo or MUGA), especially in older patients or those with cardiac risk. eviQ recommends baseline and ongoing pulmonary function assessment.
• Before each Day 1:
• CBC and differential.
• BC Cancer requires no tests before Day 15.
• Every cycle (bleomycin):
• Ask about cough and dyspnoea, and auscultate the chest.
• BC Cancer includes a chest radiograph for pulmonary toxicity in the pre-cycle assessment.
• Repeat PFTs if toxicity is suspected.
• Imaging: interim PET after Cycle 2 (Deauville 5-point scale), then end-of-treatment CT with or without PET per stage pathway.

Dose-modification principles

Summarized from BC Cancer LYABVD. Defer to your local protocol.

• Haematological:
• ANC of 0.6 × 10⁹/L or more: give 100%.
• ANC below 0.6: give 100% plus G-CSF in curative treatment. ABVD is not reduced or delayed for neutropenia alone.
• Transfuse to keep haemoglobin above 90 g/L and platelets above 20 × 10⁹/L.
• Vinblastine neuropathy:
• Dysaesthesias or areflexia: 100%.
• Difficulty buttoning or writing: 67%.
• Moderate motor neuropathy: 50%.
• Severe motor neuropathy: omit.
• Hepatic (total bilirubin):
• Doxorubicin: 2–35 µmol/L, 100%. 35–85, 50%. Above 85, omit and substitute cyclophosphamide 375 mg/m².
• Vinblastine: below 25 µmol/L, 100%. 25–50, 50%. Above 50, 25%.
• Cardiac dysfunction: BC Cancer allows replacing each doxorubicin dose with etoposide 25 mg/m² IV on the first day and 50 mg/m² PO on the second and third days.
• Pulmonary toxicity: stop bleomycin permanently if bleomycin lung is suspected. Give corticosteroids per specialist advice.
• Dacarbazine shortage: BC Cancer describes cyclophosphamide 375 mg/m² as a substitute, but only when dacarbazine is completely unavailable, with special approval, and noting there are no direct efficacy data.

Key trials & evidence

• Canellos et al. (NEJM 1992): ABVD was as effective as MOPP/ABVD and less toxic than MOPP, which established it as the North American standard.
• RATHL (Johnson, NEJM 2016): in advanced-stage HL, patients who were PET-negative after 2 cycles of ABVD were randomised to continue ABVD or switch to AVD for 4 more cycles.
• Omitting bleomycin reduced pulmonary toxicity.
• Progression-free survival was slightly lower (about 1.6 percentage points at 3 years). This narrowly missed the formal non-inferiority margin, but the difference is considered clinically acceptable.
• PET-positive patients were escalated to BEACOPP.
• Early-stage PET trials (RAPID, EORTC H10, and GHSG trials behind eviQ ID 57): these define when radiotherapy can be omitted after a negative interim PET, trading a small loss in PFS for less late toxicity.
• ECHELON-1 (Connors, NEJM 2018; Ansell, NEJM 2022): in stage III–IV HL, 6 cycles of A+AVD improved modified PFS over ABVD. At about 6 years there was an overall survival benefit (HR about 0.59).
• Costs: more neuropathy and febrile neutropenia, which is why G-CSF prophylaxis is used.
• BC Cancer LYAVDBV gives brentuximab vedotin 1.2 mg/kg (maximum 120 mg) IV on Days 1 and 15 with AVD at ABVD doses, every 28 days × 6, with mandatory G-CSF.
• SWOG S1826 (Herrera, NEJM 2024): in stage III–IV HL, N-AVD improved PFS compared with BV-AVD (HR about 0.45 at the primary analysis), with less neuropathy. Immune-related AEs were uncommon.
• BC Cancer LYAVDNIV gives nivolumab 3 mg/kg (maximum 240 mg) IV on Days 1 and 15 with AVD, every 28 days × 6.
• It covers stage IIB–IV and bulky stage II disease, and advises considering G-CSF for patients aged 60 or over.
• Overall survival data are still maturing.

Clinical pearls

• Book the interim PET for Days 21–28 of Cycle 2, close to the Cycle 3 Day 1 treatment. Earlier scans can mislead because of chemotherapy-related inflammation.
• Don't delay for neutropenia. ABVD dose intensity matters more than the ANC, and febrile neutropenia is uncommon.
• Stop bleomycin early in older patients. Many clinicians give AVD from the outset in patients over 60 or with lung disease.
• Alert anaesthesia. Prior bleomycin should prompt minimum FiO₂ during anaesthesia (BC Cancer: not above 30–40% unless essential). A medical alert bracelet is recommended.
• Encourage smoking cessation. Bleomycin and radiotherapy both damage lungs.
• Units differ. eviQ uses international units. 10 units/m² equals 10,000 IU/m².
• Watch dacarbazine infusions. Venous pain is common. Slowing the infusion or diluting further helps.
• After N-AVD, remember that immune-related adverse events such as thyroiditis can appear months later. Check TSH and educate patients.

Educational material for health professionals and students. Not a prescribing order; it does not replace your institution's approved protocol, pharmacy verification or clinical judgement.

All oncology regimen tutorials